Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disorder. The study of diverse mouse models of lupus has provided clues to the etiology of SLE. Spontaneous mouse models of lupus have led to identification of numerous susceptibility loci from which several candidate genes have emerged. Meanwhile, induced models of lupus have provided insight into the role of environmental factors in lupus pathogenesis as well as provided a better understanding of cellular mechanisms involved in the onset and progression of disease. The SLE-like phenotypes present in these models have also served to screen numerous potential SLE therapies. Due to the complex nature of SLE, it is necessary to understand the effect specific targeted therapies have on immune homeostasis. Furthermore, knowledge gained from mouse models will provide novel therapy targets for the treatment of SLE.

1. Introduction

The etiology of the autoimmune disease systemic lupus erythematosus (SLE) is considered to be a combination of multiple genetic and environmental factors whose amalgamation breaches the threshold of immune tolerance. SLE is, therefore, a complex multigenic disorder. The causative genetic factors of such disorders are believed to be allelic variants with minor functional contributions to the disease state and, individually, are not sufficient to cause overt disease. However, the combination of several of these susceptibility loci can lead to epistatic interactions that greatly enhance the overall contribution by each locus, whereby protective mechanisms are overcome and pathogenesis ensues. Hence, the capacity to tailor SLE treatments could be greatly enhanced upon the identification of the genetic variants capable of inducing autoimmunity and how their involvement can magnify SLE. Indeed, concerted efforts in human studies and mouse models have been made in that direction. The recent annotation of millions of single nucleotide polymorphisms (SNPs) in the human genome and the inception of high-throughput genotyping technologies has enabled the use of genome-wide association studies (GWAS) for this purpose. To date, SLE susceptibility has been associated to dozens of genes by GWAS [1]. While these associations offer important new insights into SLE etiology, there are logistical limitations to GWAS. Extremely large sample sets are required to achieve significant associations and extrinsic factors such as ethnicity, clinical history, and lifestyle must be considered in choosing these sets. Further, GWAS are capable of identifying genomic associations but do not characterize the function that an allelic variation confers. For this, other methods are required.

There are numerous murine models that have long been employed in an effort to understand the cellular and genetic requirements for SLE induction. The classic models of spontaneous lupus include the F1 hybrid between the New Zealand Black (NZB) and New Zealand White (NZW) strains (NZB/W F1) and its derivatives, the MRL/lpr, and BXSB/Yaa strains whereas induced models include the pristane-induced model and the chronic graft-versus-host-disease models (cGVHD). All of these models portray their own iterations of lupus-like diseases with a subset of symptoms akin to those observed in human SLE, namely, autoantibody production, lymphoid activation and hyperplasia, and lupus nephritis. In addition to spontaneous and induced lupus models, there is a plethora of genetically modified mouse models that goes beyond the scope of this paper (reviewed in [2]). Undoubtedly, genetically modified models will be used in the characterization of genes identified by GWAS, and in fact, many of these models already exist [3]. Here, we focus on what has been learned from spontaneous and induced mouse
models of SLE and how they can be used to complement the recent advances in human studies. We also highlight how murine models have been used as tools to test therapies.

2. Classic Mouse Models of Spontaneous Lupus

2.1. NZB/W F1. The NZB/W F1 is the oldest classical model of lupus generated by the F1 hybrid between the NZB and NZW strains. Both NZB and NZW display limited autoimmunity, while NZB/W F1 hybrids develop severe lupus-like phenotypes comparable to that of lupus patients [4]. These lupus-like phenotypes include lymphadenopathy, splenomegaly, elevated serum antinuclear autoantibodies (ANA) including anti-dsDNA IgG, a majority of which are IgG2a and IgG3, and immune complex-mediated glomerulonephritis (GN) that becomes apparent at 5-6 months of age, leading to kidney failure and death at 10–12 months of age [4]. Unlike SLE patients and the MRL/lpr and BXSB/Yaa mouse models, NZB/W F1 mice lack autoantibodies against RNA-containing complexes. As for SLE patients, disease in the NZB/W F1 strain is strongly biased in favor of females, and this is at least in part due to estrogen levels. Indeed ovariectomy of NZB/W F1 mice not only delayed disease onset but also decreased autoantibody titer. Meanwhile, restoration of estradiol in ovariectomized NZB/W F1 mice reestablished high numbers of DNA-specific B cells, and thereby suggests a pathogenic role of estrogen in lupus [5]. The many contributions of the NZB/W F1 model to our understanding of lupus pathogenesis have been discussed in excellent reviews [2, 4] to which the reader is referred to.

2.1.1. NZM. An accidental backcross between NZB/W F1 and NZW followed by brother-sister matings generated 27 different recombinant inbred strains of New Zealand Mixed (NZM) mice among which NZM2328 and NZM2410 are now used as lupus models [6–8]. While both NZM2410 and NZM2328 strains exhibit a highly penetrant version of the NZB/W F1 disease with an earlier onset, NZM2410 differs from NZM2328 with a weaker gender bias [7]. The NZM2328 and 2410 strains share the same autoantibody specificities as NZB/W F1 mice. The homozygosity of the NZM strains and their potential enrichment for lupus susceptibility loci has facilitated genetic analyses, and arguably their greatest contribution has been to the understanding of the genetic basis of this disease.

2.1.2. Identification and Classification of Susceptibility Loci. In 1994, Morel et al. reported the first lupus linkage analysis which identified three NZM2410 susceptibility loci, Sle1-3, as being significantly correlated with GN development [7]. The analysis of these loci showed that disease was inherited as a threshold liability, that is, the probability of presenting disease by an individual increases with the number of susceptibility alleles it carries, a concept that has been confirmed in genetic analyses of the other lupus-prone strains. The NZM2410 model was also used to show the existence of NZW-derived suppressive loci, the strongest one, Sles1, being linked to the major histocompatibility complex (MHC) class II locus H-2d [9]. These results showed that the disease outcome for a given genome represents the integration of susceptibility and resistance loci and that lupus susceptible strains carry genomes in which the susceptibility loci outweigh the resistance loci. Resistance (or transgressive) loci have subsequently been identified in other models, including lupus models (e.g., see below Lmb3 in the MRL/lpr strain).

The phenotypes contributed by each NZM2410 susceptibility locus have been determined via detailed analysis of the immunological properties of congenic strains carrying the individual loci on a C57BL/6 (B6) genetic background in comparison to B6 mice [10–16]. Briefly, Sle1 mediates the loss of tolerance to nuclear antigens leading to the production of autoreactive B and T cells culminating in the secretion of antinuclear autoantibodies. Sle2 leads to B cell hyperactivity, elevated B-1 cell levels, and polyreactive IgM antibodies. Sle3 leads to decreased levels of activation-induced cell death in CD4+ T cells, with evidence that a non-T cell compartment is involved in the expression of this phenotype [15]. Interestingly, Sles1 largely overlaps with NZM2328 Cgnz1 and Agnz1 on chromosome 1 and Sle2 with NZM2328 Adaz1 on chromosome 4 [17]. The NZM2328 loci were, however, evaluated in congenic strains in which the susceptibility intervals were replaced by nonautoimmune genomic segments, which makes impossible to directly compare the phenotypes of the respective susceptibility loci between the two strains.

As predicted by the threshold liability findings from the linkage analysis, none of the NZM2410-derived Sle loci lead to full disease presentation. Instead, the stepwise combination of each congenic interval showed that the coexpression of these three major loci is necessary and sufficient for the development of fully penetrant disease [18]. The NZM2410 strain is to date the only autoimmune model in which the subset of loci that are necessary and sufficient for disease presentation has been identified. This achievement infused added significance to the identification of the genes corresponding to those three loci. A major obstacle towards the identification of these susceptibility genes has been revealed by the studies of the Sle congenic strains, which revealed that the original quantitative trait loci (QTLs) correspond to a cluster of susceptibility loci. This finding has been best demonstrated for Sle1, which is reviewed in detail in [3], corresponds to at least seven independent loci.

2.1.3. Identification of NZM2410 Susceptibility Genes. Progress towards the identification of lupus-susceptibility genes is ongoing in several models (see below), but it is by far the most advanced in NZM2410 as reviewed in [3]. Most of the genetic variants identified in these susceptibility genes are still in the process of formal validation, and the process by which they contribute to lupus pathogenesis is still largely unknown. However, variations in many of these genes has been directly associated with human lupus, which is by itself a strong validation of the mouse findings. The NZM2140 allele of Fgr2b, which encodes for a negative regulator of B-cell signaling, contributes to an
autoimmune phenotype [19] and a large number of studies have established an association between FCGR2B variants and human SLE [20]. Consequently, the involvement of Fcgr2b in lupus pathogenesis has been validated in both mice and humans at the genetic and functional levels. Similarly, polymorphisms in Cr2, which encodes the complement receptor type 2 that acts as a B-cell coreceptor, contribute to the Sle1c1 phenotypes [21, 22]. A common CR2 haplotype is more frequent in SLE patients than in healthy controls, and novel CR2 splice variants are expressed on the follicular dendritic cells of SLE patients [23, 24]. Sle1b corresponds to polymorphisms in four signaling lymphocytic activation molecule (SLAM) family member genes [25], including Ly108, which was directly implicated in the regulation of B-cell tolerance [26]. Variants of SLAMF3 (LY9) and SLAMF4 (CD244) have been associated with human SLE [27, 28]. Finally for the Sle1 subloci, Sle1a1 corresponds to the expression of a novel splice isoform of the Pbx1 gene that is associated with increased CD4+ T cell activation in both mice and humans (Cuda et al., in revision). Pbx1 function in T cells is unknown, and studies are ongoing to uncover the mechanisms linking Pbx1 expression and T cell phenotypes. The Sle3 locus induces a complex phenotype that includes myeloid cell-induced CD4+ T-cell activation [29] and mild GN [12]. Polymorphisms in kallikrein (Klk) genes, which are located in the Sle3 interval, have been associated with increased susceptibility to nephritis in the mouse and in SLE patients [30].

2.2. MRL/lpr

2.2.1. Derivation and Phenotype of the MRL/lpr Strain. The MRL strain was developed from several crosses of inbred strains. Specifically, most of the MRL genome was derived from the LG/J strain with minor contributions from C3H/Di, C57BL/6, and AKR/J [4]. Initial characterization of MRL substrains revealed one strain, termed MRL/lpr, which developed an SLE-like phenotype characterized by lymphadenopathy due to an accumulation of double negative (CD4−CD8−) and B220+ T-cells. These mice displayed an accelerated mortality rate, and unlike the NZB/W F1 mice, both males and females were significantly affected. In addition, the MRL/lpr substrain had high concentrations of circulating immunoglobulins, which included elevated levels of autoantibodies such as ANA, anti-ssDNA, anti-dsDNA, anti-Sm, and rheumatoid factors, resulting in large amounts of immune complexes [31]. This accelerated phenotype was attributed to a recessive autosomal mutation termed lymphoproliferation (lpr). The lpr mutation, located on chromosome 19, alters transcription of the Fas receptor [32].

2.2.2. Effect of Fas Signaling Deficiency in Disease Development. Fas is a surface-bound receptor belonging to the tumor necrosis factor receptor (TNF-R) family that induces apoptosis upon interacting with its ligand, Fasl. [33]. The defects in Fas transcription are caused by an insertion of the retrotransposon ETn which leads to aberrant, nonfunctional transcripts due to alternative splicing of the Fas gene [34]. Studies on B-cells and T-cells from MRL/lpr mice, which both express Fas, confirmed a defect in apoptosis due to the lack of functional Fas receptor [35]. Furthermore, a mutation on the FasL gene, termed generalized lymphoproliferative disease (gld), was shown to cause an autoimmune disorder similar to the lpr mutation [36, 37]. This recessive mutation, located on chromosome 1, caused a single amino acid change (Leu > Phe) which prevented FasL from binding to its receptor. Therefore, a deficiency in Fas signaling results in an SLE-like phenotype due to defective Fas-mediated apoptosis. In humans, defective Fas signaling can lead to the development of autoimmune lymphoproliferative syndrome (ALPS) which shares many symptoms with SLE although GN is uncommon in ALPS patients [38].

The SLE symptoms attributed to Fas deficiency in MRL/lpr mice are dependent on both CD4+ T-cells and B-cells as their absence decreased autoimmunity [39, 40]. Further studies on Fas-deficient T-cells using the (C57BL/6 × MRL)F1 autoimmune strain resulted in lymphopenia as activated T-cells upregulated FasL, promoting the apoptosis of peripheral lymphocytes [41]. Meanwhile, in the presence of the lpr mutation, the nonautoimmune C3H/HeJ and C57BL/6j strains developed lymphoproliferation and had a reduced lifespan [42]. In addition, high levels of IgM and IgG antibodies, in particular autoantibodies against DNA and IgG, were detected in these strains. Conditional deletion of Fas in T-cells, B-cells, or both T-cells and B-cells in nonautoimmune C57BL/6 mice resulted in higher levels of autoantibodies but lymphoproliferation was not observed. To reconstitute the phenotype seen in lpr mice, Fas deletion had to be present in both lymphoid and nonlymphoid cells [41]. In particular, Fas deficiency in dendritic cells (DCs) led to systemic autoimmunity as it induced elevated ANA, splenomegaly, and accumulation of mature DCs [43].

2.2.3. Effect of the MRL Genetic Background in Disease Development. Expression of the lpr mutation in either the C3H/HeJ and C57BL/6j strains did not result in nephritis [44]. In contrast, Fas-sufficient, MRL+/+ mice displayed the pathological effects of nephritis though onset of symptoms was significantly delayed when compared to MRL/lpr mice. Therefore, the MRL background genes play an important role in the development of disease. Characterization of (MRL-Fasl+/− × C57BL/6-Fasl+/−)F2 mice revealed four susceptibility loci, Lmb1−Lmb4, that were linked to anti-dsDNA autoantibodies and glomerulonephritis [45]. In particular, studies on congenic mice showed that Lmb3, located on the telomeric region of chromosome 7, had a significant effect on lymphoproliferation and enhanced T-cell proliferation while T-cell apoptosis was reduced [46]. Recently, a single nonsense mutation (C > T) in the Coronin-1A gene, located within the Lmb3 susceptibility locus, was identified in the Scripp substrain of C57BL/6 and it resulted in suppression of disease when crossed to MRL/lpr [47]. Coronin-1A binds F-actin and prevents its assembly and depolymerization. Nonfunctional Coronin-1A, from the mutant Lmb3 locus, was associated with increased T-cell apoptosis and reduced T-cell activation and proliferation. Further characterization
of the MRL background should reveal additional candidate genes that promote autoimmunity in MRL/lpr mice.

2.3. BXSB/Yaa

2.3.1. Derivation and Phenotype of the BXSB/Yaa Strain. Lymphoproliferation was observed in males of an (C57BL6/J × SB/Le)F1 intercross and its backcross to SB/Le. A recombinant inbred strain, BXSB/Mp, was derived from this backcross, and nearly 100% of BXSB mice develop a lupus-like disease that was much more severe with earlier onset in males [48, 49]. The disease phenotypes include secondary lymphoid tissue hyperplasia, immune complex-mediated GN, monocytosis, hypergammaglobulinemia, antinuclear and antienrythrocytic autoantibodies, and high-serum retroviral glycoprotein gp70 titers [48, 50]. Mean survival is roughly 5 months in males and 14 months in females, and the major cause of death is proliferative GN [48, 50].

2.3.2. Effect of the Y Chromosome in Disease Development. The fact that disease is greatly accelerated in BXSB males suggested the presence of a susceptibility element on the Y chromosome or that sex hormones play a role in this model. Orchiectomy did not delay onset or severity in BXSB males, while ovariectomy did not exacerbate disease in females, ruling out a hormonal effect [51]. Moreover, consomic studies showed that the BXSB-derived Y chromosome exacerbated disease when combined with either NZW or MRL genetic backgrounds [52, 53]. Thus, an element, termed Y-linked autoimmune accelerator (Yaa), was deemed to be responsible for the acute disease in BXSB males.

It is now known that Yaa is due to a translocation of the telomeric end of the X chromosome to the Y chromosome, resulting in the duplication of at least 16 genes and a ~2-fold expression in many of these genes [54, 55]. Among these is Toll-like Receptor 7 (Tlr7), which encodes an innate pattern recognition receptor found in B cells and antigen presenting cells (APCs). TLR7 is activated by viral ssRNA and signals through the myeloid differentiation primary response gene 88 (MyD88) adaptor resulting in nuclear factor κB activation and expression of type I IFN (IFN I) and other proinflammatory cytokines [56]. Importantly, it has been shown that TLR signaling can act as signal 2 in B cell activation and that those interactions with endogenous RNA ligands are sufficient for autoreactive B cell activation [57, 58]. Additionally, disease activity is extremely sensitive to TLR7 expression. Where a 2-fold increase by the Yaa translocation only results in overt disease in the presences of other susceptibility alleles, greater increases in expression result in a Tlr7 dose-responsive disease that does not require other lupus susceptibility loci [59]. Moreover, deletion of the endogenous copy of Tlr7 from the X chromosome abrogates Yaa-induced monocytosis, lymphoid activation, splenomegaly, GN, and mortality [59–61]. Thus, Tlr7 gene duplication has been deemed to be the major functional contributor to the Yaa phenotype. Shen et al. have recently reported a human allele of the TLR7 gene with associated risk for SLE development in males [62]. This human susceptibility allele increased the expression of TLR7 and of IFN I-regulated genes in blood monocytes. In this way, TLR7 dose increases lupus susceptibility in both mice and humans.

It is also likely that there is a minor contribution from other genes in the translocated Yaa interval, since endogenous Tlr7 deletion does not eliminate all Yaa-induced phenotypes. Lupus prone Yaa+/− · Tlr7− mice still display some humoral abnormalities, increased autoantibody production, and a decreased marginal zone (MZ) B cell compartment as compared to lupus prone Yaa− · Tlr7+ mice [60, 61].

2.3.3. Effect of the BXSB Genetic Background in Disease Development. While the Yaa allele is certainly the most distinguishable feature of the BXSB model, it is not the whole story. In fact, the Yaa mutation alone is not sufficient to cause disease. This is clearly illustrated by the fact that nonlupus prone strains, such as B6 and CBA, that are consomic for the BXSB Y chromosome do not develop disease [52, 63]. The BXSB MHC (H-2b/d) locus plays a dominant role in disease activity since congenic BXSB.H-2d/d mice have a less severe syndrome, while BXSB.H-2b/d and BXSB.H-2b/b mice have the full disease [64]. However, as stated above, B6· Yaa (H-2b/b) mice have no malady. Therefore, there are non-MHC-linked autosomal elements in the BXSB genome that contribute to disease development.

Quantitative trait linkage analyses have identified BXSB susceptibility loci on chromosomes 1, 3, and 13 (Bxs1–6) [65, 66]. These loci are all derived from the parental SB/Le strain except for Bxs5 on chromosome 3, which is a transgressive allele derived from B10 [49]. Bxs1–4 are all located on chromosome 1 and studies using congenic mice confirmed that these loci confer lupus phenotypes [67]. Interestingly, Bxs3 overlaps with Sle1 and seems to have the most robust effect. This suggests that like Sle1, Bxs3 may itself contain multiple susceptibility loci, some of which might be allelic. Of the four loci located on chromosome 1, only Bxs2 has a proposed candidate gene. RNA and protein levels of the innate scavenger receptor Marco (macrophage receptor with collagenous structure) are reduced in the macrophages of Bxs2-containing congenic mice. This leads to a defect in clearance of apoptotic material, which is generally associated with the development of systemic autoimmunity [68].

Bxs6 on chromosome 13 is linked to increased serum gp70 and anti-gp70 autoantibody. The presence of Yaa greatly enhances Bxs6 resulting in nephritis due to deposition of the associated gp70 immune complexes (gp70IC) in glomeruli. Gp70 is a glycoprotein subunit encoded by the viral envelope env gene of endogenous retroviruses that is produced by hepatocytes as an acute phase protein [69]. Though not proven conclusively, there is a good deal of evidence for a role of endogenous retroviruses in lupus pathogenesis (reviewed in [70]). Bxs6 overlaps with two other loci, NZW-derived Sgp3 [71] and 129-derived Gv1 [72], which are also involved in the regulation of serum gp70 levels. This positional and functional relationship between these three loci suggests that they may be caused by the same gene(s). Further, TLR7 activation causes Sgp3-mediated upregulation of serum gp70, in much the same way that Yaa enhances of Bxs6-mediated upregulation of serum gp70 [73]. Sgp3 has been the most extensively analyzed and has
been recently narrowed down to a 5.42 Mb region in which 21 of the 30 genes encode Krüppel-associated box zinc-finger proteins (KRAB-ZFP) that are capable of suppressing proviral transcription through the heterochromatization viral integration sites [70]. KRAB-ZFPs are, therefore, the primary candidate genes for Sgp3 and likely for Bxs6.

3. Induced Models of Lupus

3.1. The Pristane-Induced Lupus Model. Unlike the mouse models mentioned above, in which genetic factors play the major role, induced mouse models develop lupus after exposure to certain environmental triggers. Intrapерitoneal injections of pristane (2, 6, 10, and 14 tetramethylpentadecane, TMPD), an isoprenoid alkane found at high concentration in mineral oil, is a standard method to obtain ascitic fluid enriched in monoclonal antibodies. However, pristane administration in BALB/c mice induces autoantibodies characteristic of lupus, such as antiribonucleoprotein (RNP) antibodies (anti-Su, anti-Sm, and anti-U1RNP), anti-DNA, and anti-histone, to a level comparable to that found in MRL/lpr mice [74, 75]. Pristane-treated mice also have immune-complex deposition in the kidney leading to severe proteinuria and nephritis [75]. Besides the BALB/c strain, almost all mouse strains are susceptible, to a variable extent, to the pristane-induced production of antibody and lupus manifestations [76], confirming that environment has a considerable importance in lupus. Like human SLE patients and NZB/W F1 model, pristine-induced lupus is more severe in females than in males, at least in SJL/J strain [77].

3.1.1. Cytokines in Pristane-Induced Lupus. Inflammatory cytokines have critical effects in pristane-induced lupus. By using BALB/c IL-6−/− mice, it was found that anti-ssDNA, dsDNA, and chromatin antibodies are highly IL-6-dependent whereas anti-RNP/Sm and anti-Su antibodies have no obvious correlation with IL-6 levels [78]. Interestingly, anti-dsDNA antibodies generally develop after renal disease, which indicates that these autoantibodies do not participate in the development of nephritis in this model. When pristane was administered to lupus-prone NZB/W F1 mice, it greatly accelerated the disease and lead to large amounts of IL-12, anti-Sm, anti-Su, and anti-RNP autoantibody production, implying a link between IL-12 and these anti-RNP autoantibodies [79]. This was confirmed by the fact that IL-12 deficiency prevented pristane-treated mice from anti-RNP/Su IgG production and nephritis [80]. These studies revealed that the production of different autoantibodies may be induced by different cytokine pathways and contribute differently to end-organ disease. In another study, IFN-γ deficiency significantly protected pristane-treated BALB/c mice from autoantibody production and renal disease whereas IL-4 deficiency has no effect [81]. Thus, pristane-induced lupus may be attributable to a shift of the T-helper cell subsets, Th1-Th2, balance.

Overexpression of IFN-I and interferon-stimulated genes (ISGs, also called “interferon signature”) has been closely associated with ANA production and disease severity in SLE patients [82]. Pristane-induced lupus is the only animal model that shows an interferon signature. Indeed, studies in pristane-induced lupus have revealed that IFN-1 receptor deficiency (IFNAR−/− or IFNAR2−/−) completely erased the interferon signature, eliminated anti-RNP, anti-Sm, and anti-dsDNA autoantibodies, reduced anti-ssDNA and anti-histone IgG, and significantly improved GN [83, 84]. IFN-I may contribute to autoantibody production by regulating TLR7/9 expression and activation in B cells [84]. IFN-I also seems to regulate another autoantibody mediator, IL-12, as IFNAR−/− mice fail to elevate IL-12 level following pristane treatment [83].

Instead of plasmacytoid dendritic cells (pDCs) which have been identified as the major producers of IFN-I in human lupus [85], an accumulation of peritoneal immature Ly6Chigh monocytes is the major source of IFN-I in pristane-treated mice. Depletion of this cell population rapidly abolished the interferon signature and autoantibody production in pristane-treated mice [86]. IFN-I in turn mediates the recruitment of Ly6Chigh immature monocytes to the peritoneum through the upregulation of chemokines such as CCL2, CCL7, and CCL12. IFN-1 also prevents the maturation of monocytes, with a twofold effect: firstly, immature monocytes are a major source of IFN-1. Therefore, blocking of monocyte maturation results in a vicious feedback loop of IFN-1 production, monocyte recruitment, and block in an immature state. Secondly, failure of monocyte maturation into phagocytic Ly6Clow monocytes/macrophages leads to an impaired clearance of cell debris, which is an important stimulus of inflammation and autoantibody production [87]. Thus, IFN-I production by Ly6Chigh monocytes may be a major cause of chronic inflammation and SLE.

Pristane induces IFN-I production exclusively through the TLR7/MyD88 pathway [88]. TLR7 deficiency not only abolishes pristane-induced IFN-I production but also eliminates autoantibody production and renal disease, indicating a key role of TLR7/MyD88/IFN-I pathway in this model [88, 89]. FcR γγ recognizes the Fc portion of extracellular IgG and is proposed to mediate the intake of immune complex that subsequently activates endosomal TLRs, such as TLR7 [90]. However, IFN-I and autoantibody production are FcRγ-independent in pristane-induced lupus [88]. Therefore, the modulation of TLR7 by pristane does not rely on immune complexes. The exact mechanism of pristane-mediated TLR7 activation remains to be identified.

3.1.2. Other Manifestations of Pristane-Induced Lupus. In addition to nephritis, hemorrhagic pulmonary capillaritis and arthritis have also been identified in pristane-treated mice [91]. 14 days after a single dose of pristane injection, bronchoalveolar lavage (BAL) fluid becomes hemorrhagic with elevated neutrophil counts and high levels of IL-6 and IL-10. Perivascular infiltrates of immune cells and endothelial injury are also found in the lung of pristine-treated mice [91]. Some SLE patients also develop pulmonary capillaritis [92], and whether pristane-induced hemorrhagic pulmonary capillaritis can serve as a valid model for human lupus lung disease remains to be verified. The arthritis symptoms in
pristane-induced lupus include synovial hyperplasia, periostitis, and progressive marginal erosions [93, 94]. Pristane-induced arthritis is tumor necrosis factor (TNF-α) mediated, as treatment with neutralizing anti-TNF-α antibody ameliorates the arthritis symptoms [95]. The broader extension of end-organ targets as well as the preeminent role plays by IFN-α make pristane-induced lupus arguably a model of choice for mechanistic studies of human lupus.

3.2. Induced Chronic Graft-versus-Host Disease

3.2.1. Highlights and Advantages of the Parent into F1 Method. Various models of induced graft-versus-host disease (GVHD) have been used as models of lupus. As with the pristane-induced model, these models require only a single injection of donor cells to induce a lupus-like syndrome. The disease process is reproducible, with severity correlating to the number of allografted cells. Because this method induces a rapid disease onset from a known starting point, the study of lupus induction is greatly facilitated as compared to the spontaneous models of lupus. As an example, autoantibodies are detectable as early as 10–14 days after induction in these models whereas it can be several weeks to months after birth for the same phenotype to develop in spontaneous lupus models. Further, since the donor T cells undergo activation and expansion, they are relatively easy to observe by flow cytometry, allowing the study of the effect of various modifications on the donor as well as the host cells.

In the parent into F1 (P → F1) model, lymphocytes are transferred into a semiallogeneic recipient such that the donor cells react to the host, and the host is tolerant to the donor allograft. (reviewed in [96]). Depending on the model used, an acute or a chronic GVHD (aGVHD or cGVHD) ensues. In most models of P → F1, such as B6 into (B6 × DBA)F1, aGVHD is induced by donor CD8+ T cells, which manifests as severe lymphopenia of host cells as well as strain-specific connective tissue diseases. Host B cells are most sensitive to this CTL killing and may be almost completely ablated after 2 weeks, followed by host APCs, then CD4+ T cells, and finally host CD8+ T cells. Conversely, DBA into (B6 × DBA)F1 (DBA → BDF1) results in cGVHD, a donor CD4+-mediated response resulting in massive host polyclonal B cell activation, expansion, and immunoglobulin production. This chronic condition exhibits several similarities to SLE, including ANA, lupus-specific autoantibodies, and immune complex-mediated GN. Another feature of DBA → BDF1 is that the lupus pathogenesis in this model is more severe in females than males allowing the study of gender-biased lupus etiology [97, 98]. Additionally, DBA → BDF1 allows for identification of CTL-promoting treatments in vivo, such as with agonist anti-CD40 antibody, IL12, and antagonist anti-CD80 antibody [99–101].

The induction of a GVHD response is caused by a diminished capacity for DBA CD8+ T cells to produce a CTL response to the F1 host. Correspondingly, B6 into (B6 × DBA)F1 will result in GVHD if the donor cells are depleted of CD8+ T cells. The ensuing lupus phenotypes include ANA, anti-dsDNA and anti-RBC autoantibodies, and GN. The major advantage of B6(-CD8) → F1 over the DBA → BDF1 model is that genetic modification of the donor cells can be examined due to the plethora of knockout and transgenic B6 mice. To this extent, this model has demonstrated that partial CTL deficiency due to the lack of perforin (B6-Ppf-/- → F1) or Fas/FasL (B6-gld → F1) was sufficient to induce a CD4+-mediated cGVHD phenotype.

B6(-CD8) → F1 was also used as a complement of B6 → F1 (not depleted of CD8+ T cells) to study in vivo mechanisms that mediate the overall donor CD8+ T cell versus CD4+ T cell response, and thus result in aGVHD versus cGVHD. One such study demonstrated that TNFα blockade inhibited the early induction of CTLs and skewed T cell cytokine profile to antibody promoting IL-4, IL-6, and IL-10, resulting in an antibody mediated cGVHD response [102]. This novel finding revealed the potential of TNFα-blocking treatments to instigate humoral autoimmunity. Another study described a positive role in B6(-CD8) → F1 cGVHD and a negative role in B6 → F1 aGVHD for the TNF family member, TRAIL, highlighting its role in the promotion of lupus [103].

3.2.2. B6·H-2bm12 → B6 cGVHD. When B6·H-2bm12 lymphocytes, whose MHC II locus confers a 3 amino acid substitution in H-2b, are transferred into B6 hosts with the wild-type H-2b locus, cGVHD develops. The lupus-like phenotypes in this model include ANA, anti-dsDNA, antichromatin, and anti-Sm autoantibodies, and GN [104]. Since the MHC disparity between donor and host is limited to class II in this model, CD8+ T cell depletion of donor lymphocytes is not required. Also, since this model works equally well with B6·H-2bm12 → B6 and B6 → B6·H-2bm12, donor and host gene modifications can be examined by the use of knockout and transgenic mice.

Although cGVHD has been shown to be mediated through donor CD4+ T cells and host B cells, an interesting facet of cGVHD was revealed using this model. The observation that a response did not occur in CD4+/- hosts indicated a role for endogenous CD4+ T cells [189]. Further, B cells raised in such an environment had intrinsic defects in their ability to produce an allosresponse [190]. It has been recently reported that B cells require “nurturing” during early ontogeny in the form of IL-4 [191]. In lieu of endogenous CD4+ T cell nurturing, large doses of rIL-4 or agonist anti-CD40 antibody in CD4+/- hosts during this critical developmental period were also sufficient for B cells to develop with alloreactive potential.

4. Therapeutic Studies for SLE on Mouse Models

Mouse models of SLE have been used not only to dissect disease mechanisms but also to test potential therapies. In addition to validating targets, testing drugs on mouse models of SLE has proved indispensable before they go to clinical trials. We have summarized the major therapeutic studies that have been conducted on mice models of SLE in Table 1. Several components of the immune system, such as cytokines, B-cells, T-cells, and hormones have been identified as potential targets for therapy, which have been
Table 1: Summary of treatments tested in mouse models of lupus, their targets, proposed mechanisms, outcomes in the mouse, and follow up in clinical trials.

| Targets | Treatment | Mouse model | Mechanisms | Main outcomes | Ref | Clinical trial |
|---------|-----------|-------------|------------|---------------|-----|----------------|
|         |           |             | Targeting cytokines |               |     |                |
| IL-6    | IL-6R mAb | MRL/lpr     | Inhibits IgG class switch | Nephritis, anti-dsDNA Ab↓ | [105] | Tocilizumab* A Phase I trial showed both decreased disease activity and side effects [106] |
|         | IL-6R mAb | NZB/W F1    | Decreases IL-10, increases TNF-α | Survival↑, IgG ANA↓, proteinuria↓ | [107] |                |
|         | IL-6 mAb | NZB/W F1    | Suppresses autoreactive B cell and T cell | Nephritis, anti-dsDNA Ab↓ | [108] |                |
| IL-10   | IL-10 inhibitor (AS101) | NZB/W F1 | Decreases IL-10, increases TNF-α | Delayed onset, anti-DNA Ab↓, proteinuria↓, glomerular deposition↓ | [109] |                |
|         | IL-10 mAb | NZB/W F1    | Neutralizes IL-10, increases TNF-α | Delayed onset, survival↑, ANA↓ | [111] |                |
|         | rIL-10    | MRL/lpr     | Suppresses Th1 response | IgG2a anti-dsDNA↓ | [112] |                |
|         | AAV-IL-10 (low exp.) | B6-Sle1-Sle2-Sle3 | Suppresses Th1 response | ANA↓, GN↓, T cell activation↓ | [113] |                |
| TNF-α   | rTNF-α    | NZB/W F1    | Decreases cellular response | Delayed onset, survival↑ | [114] |                |
| IFN-α   | IFN-α kinoid vaccination | NZB/W F1 | Induces anti IFN-α neutralizing Ab | Delayed onset, survival↑, proteinuria↓ | [116] |                |
| IFN-β   | IFN-β     | MRL/lpr     | Reduces both cellular and humoral responses and cytokine production | Survival↑, proteinuria↓, skin lesions↓, ANA↓, splenomegaly↓ | [119] |                |
| IFN-γ   | IFN-γ cDNA vaccination | MRL/lpr | Induces anti IFN-γ neutralizing Ab | Survival↑, lymphoid hyperplasia↓, ANA↓, GN↓ | [120] | AMG 811 Phase I trial in progress |
|         | IFN-γ mAb | NZB/W F1    | Reduces both cellular and humoral responses and cytokine production | Survival↑, proteinuria↓, anti-DNA Ab↓ | [121] |                |
| IL-17   | Rock2 inhibitor (Fasudil) | MRL/lpr | Inhibits IRF4 phosphorylation and reduces IL-17 and IL-21 production | Anti-dsDNA Ab↓, glomerular deposition↓, proteinuria↓ | [122] |                |
| IL-21   | IL-21R-Fc | MRL/lpr     | Decreases T cell numbers and alters B cell functions | Total Ig↓, anti-dsDNA Ab↓, proteinuria↓, skin lesions↓, lymphadenopathy↓ | [123] |                |
| IL-18   | IL-18 cDNA vaccination | MRL/lpr | Induces anti-IL-18 neutralizing Ab | Survival↑, GN↓, IFN-γ↓ | [124] |                |
## Table 1: Continued.

| Targets | Treatment | Mouse model | Mechanisms | Main outcomes | Ref | Clinical trial |
|---------|-----------|-------------|------------|---------------|-----|----------------|
| BAFF   | Adenovirus-BAFF-R-Ig | NZM2410 | Depletes B cell, decreases T cell activation and myeloproliferation | Survival↑, proteinuria↓, splenomegaly↓, reverses disease | [125] | Belimumab |
| Anti-BAFF-Ig | B6-lyn−/− | | | | [129] | |
| BAFF and APRIL | Human TACI-Ig | NZB/WF1 | Blocks BAFF and APRIL signaling | Survival↑, proteinuria↓, no significant change in anti-dsDNA Ab level | [130] | Atacicept |
| Adenovirus-tACI-Ig (w/ or w/o CTLA4-Ig co-administration) | NZB/W F1 | Blocks BAFF and APRIL signaling splenic B cell depletion | Survival↑, delayed onset, ANA↓, proteinuria↓, nephritis↑, reverses disease only when CTLA4-Ig coadministered | [131] | |
| Adenovirus-tACI-Fc | MRL/lpr, NZB/W F1, | Blocks BAFF and APRIL signaling | In MRL/lpr: survival↑, GN↓, proteinuria↓, In NZB/W F1: anti-TACI antibodies neutralized TACI-Fc | [132] | |
| Adenovirus-tACI-Ig | NZM2410 | Blocks on BAFF and APRIL signaling | Survival↑, proteinuria↓, splenomegaly↓, reverses disease | [125] | |
| CD20 | Anti-CD20 mAb | MRL/lpr | ADCC, CDC | Serum Ab and ANA↑, nephritis↓, proteinuria↓, dermatitis↑ | [133] | Rituximab Failed to reach primary end point [134, 135] |
| Anti-CD20 mAb | NZB/W F1 | ADCC, CDC | Treatment on 12–28-wk-old mice ameliorates disease, while treatment on 4-wk old mice hastens disease | [137] | Ocrelizumab Phase III terminated [136] |
| CD22 | Anti-CD22 mAb | NZB/W F1 | ADCC, targets inhibitory receptor | Able to deplete several B cell subsets. No significant effect on improving survival | [137] | Epratuzumab Phase IIb trial showed positive result [138, 139] |
| CD79 | Anti-CD79 α and Anti-CD79 β mAb | MRL/lpr | | Survival↑, IgG antichromatin↑, skin lesions↑: Inflammatory infiltrates↑ | [140] | |
| Proteasome | Proteasome inhibitor bortezomib | NZB/W F1 and MRL/lpr | Eliminates both short-lived and long-lived plasma cells | Survival↑, ANA↑, GN↓ | [141] | |
| Targeting T cell-APC interactions | | | | | |
| CTLA4-Ig | NZB/W F1 | Inhibits B7-CD28 interaction | Survival↑, ANA↑ | [142, 143] | Abatacept The ACCESS trial is in progress [144] |
| Targets | Treatment | Mouse model | Mechanisms | Main outcomes | Ref | Clinical trial |
|---------|-----------|-------------|------------|---------------|-----|----------------|
| CD28-B7 | Adenovirus-CTLA4-Ig | NZB/W F1 | Inhibits B7-CD28 interaction | Survival, ANA, GN↑ | [145] |
|         | CTLA4-Ig transgene | B6 lyn−/− | Inhibits B7-CD28 interaction | Myeloid hyperplasia, splenomegaly, IgG ANA↓, renal disease unaffected | [146] |
|         | CTLA4-Ig and anti-gp39 | NZB/W F1 | Simultaneously inhibits B7-CD28 and CD40/gp39 interaction | Survival, ANA↓, GN↓, effects are more significant than CTLA4-Ig alone | [143] |

Targeting T follicular helper cells

| CD3 | Nasal anti-CD3 Ab | NZB/W F1 | Downregulates the expression of IL17 and IL21 by Tfh cells | ANA↑, GN↓ | [147] |

ICOS-B7RP-1 | anti-B7RP-1 Ab | NZB/W F1 | Downregulates ICOS and reduces Tfh cell number | Survival↑, anti-dsDNA Ab↓, proteinuria↓ | [148] |

Targeting other receptors

| FcgRIIB expressing retrovirus | NZM2410, BXSB, B6Fcgr2b−/− | Restores FcgRIIB level | ANA↓, immune complex deposition↓, proteinuria↓, GN↓, lung pathology↓ | [149] |
| TLR7/TLR9 | Immunoregulatory sequence (IRS) 954 | NZB/W F1 | Reduces the production of IFN-α | Survival↑, ANA↑, proteinuria↑, GN↑ | [150] |

Programmed death-1 (PD-1) | Neutralizing PD-1 Ab | NZB/W F1 | Promotes suppressive CD8+ T cells | Survival↑, delayed nephritis, IgG↓, anti-dsDNA IgG↓ | [151] |

Targeting cell signaling

| Syk inhibitor R788 | NZB/W F1 | Blocks B cell receptor (BCR) and FcR signaling | Survival↑, proteinuria↓, renal disease↓ | [152] |
| Syk inhibitor R788 | MRL/lpr or BAK/BAX−/− | Blocks BCR and FcR signaling | Skin lesions↓, lymphadenopathy and splenomegaly↓, renal disease↓ | [153] |

| PI3K y AS605240 compound | MRL/lpr | Reduces T and B cell activation | Survival↑, renal infiltrates↓, GN↓ | [154] |

mTOR | Rapamycin | NZB/W F1 | Immunosuppression | Survival↑, anti-dsDNA Ab↓, splenomegaly↓, albuminuria↓ | Rapamycin A small scale trial showed efficacy [156] |

Cellular therapies

| Regulatory B cells (Breg) | Anti-CD40 injection | MRL/lpr | Agonistic anti-CD40 expands Breg | Survival↑, anti-dsDNA Ab↓, proteinuria↓, skin lesions↓ | [157] |
| Regulatory T cells (Treg) | Adoptive transfer of ex vivo expanded Treg | NZB/W F1 | T cell suppression | Survival↑, renal IC deposition↓, proteinuria↓, GN↓ | [158, 159] |

| Umbilical cord mesenchymal stem cells (MSC) | MRL/lpr | Immunosuppressive and anti-inflammatory properties | anti-dsDNA Ab↓, Proteinuria↓, renal disease↓ | [160] |
| Umbilical cord mesenchymal stem cells (MSC) | NZB/W F1 | Immunosuppressive and anti-inflammatory properties | Survival↑, anti-dsDNA Ab↓, proteinuria↓, renal disease↓ | [161] |
| Targets | Treatment | Mouse model | Mechanisms | Main outcomes | Ref | Clinical trial |
|---------|-----------|-------------|------------|---------------|-----|----------------|
| Bone marrow derived mesenchymal stem cell (BM-MSC) | | NZB/W F1 | Inhibition of B cell proliferation and differentiation dependent on IFN-γ | Glomerular IC deposition, lymphocytic infiltration, glomerular proliferation, anti-dsDNA Ab and proteinuria unaffected | [163] | |
| Sex hormone modulation | | | |
| Estrogen | Nafoxidine | NZB/W F1 | | Delayed onset, survival, ANA, proteinuria | [164] | Tamoxifen A small-scale trial showed no effect [165] |
| Estrogen | Tamoxifen | NZB/W F1 | Reduces IgG3 ANA production | Survival, IgG3 ANA, proteinuria, thrombocytopenia, glomerular deposits | [166], [167] | Fulvestrant (estrogen receptor downregulator) A small-scale trial showed some efficacy [168] |
| Estrogen | Raloxifene | NZB/W F1 | Inhibits B cell function | Anti-DNA Ab, kidney damage | [169] | |
| Estrogen | Indole-3-carbinol | NZB/W F1 | Blocks B cell and T cell differentiation | Survival, ANA, nephritis | [170] | |
| Androgen | Androgen treatment on castrated female | NZB/W F1 | Unspecified | Survival, IgG ANA | [171] | Dehydroepiandrosterone Little clinical effect [172] |
| Androgen | Androgen treatment | NZB/W F1, MRL/lpr | Unspecified | Survival, anti-DNA Ab | [173] | |
| Peptide-based immunotherapy | | | | | | |
| Laminin | Laminin derived peptides | MRL/lpr | Laminin derived peptides competitively bind with ANA and prevent their deposition in the kidney | Survival, proteinuria, GN | [174] | |
| HSC chaperone protein | U1-70K snRNP derived peptide administered in saline (P140) | MRL/lpr | Impairs autoimmune T cell response | Survival, proteinuria, anti-dsDNA Ab | [175], [176] | P140 A phase IIa study showed positive result [177] |
| Autoreactive B and T cells | Histone peptide H2B10−33, H416−39, H471−94 (SWR/ NZB)F1 | | Impairs autoimmune B and T cell | Survival, proteinuria, ANA | [178] | |
| Suppressive CD8+ T cells | pCONS | NZB/W F1 | Promotes suppressive CD8+ T cells by regulating Foxp3 and PD-1 | Survival, nephritis, ANA | [179], [181] | |
| Unclear | CDR1 of human anti-DNA Ab (hCDR1) | NZB/W F1 | Modulation of cytokines, regulatory T cells and T cell apoptosis | ANA, nephritis, CNS symptoms | [182] | hCDR1 A small-scale trial showed positive result [182] |
| Histone deacetylase inhibitors TSA and SAHA | Histone deacetylase inhibitors TSA and SAHA | MRL/lpr | Decreases transcription of key cytokines involved in SLE | Splenomegaly, proteinuria, renal disease | [183] | |

Other therapies

---

Table 1: Continued.
tested in mouse models of lupus, most often in a preventive rather than therapeutic mode. Some of the most successful therapeutic approaches have lead to clinical trials, several of which are currently in progress. Among them, Belimumab, a humanized monoclonal antibody directed against B-cell activating factor (BAFF), is the first biologic treatment that has met clinical trial end points and has been recommended for SLE treatment. BAFF regulates the survival of B-cells. It was determined that lupus-prone mice and SLE patients have elevated levels of BAFF. Additionally, nonautoimmune transgenic mice overexpressing BAFF showed lupus-like symptoms [130]. Targeting BAFF receptors (BAFF-R, TACI, or BCMA) in the NZM2410 and MRL/lpr lupus mouse models was effective in reducing disease symptoms [125, 132]. Murine studies targeting the BAFF pathway were followed by clinical trials targeting BAFF in SLE patients. The success of Belimumab in clinical trials is considered a breakthrough in the search for new therapies for SLE [126, 127]. This example serves to illustrate the important role mouse models play in the development of effective treatments for this complex human disease.

A major limitation for drug trials in humans is that although physiological parameters are collected, it is difficult to determine changes in internal organs, such as the lymphoid organs and the kidneys. For example, the anti-CD20 antibody (Rituximab) is able to deplete B cells in humans through antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [192]. However, this data was mainly obtained from human peripheral blood B cells, which represents only 2% of the total B cells in the body [193]. Studies in mice have shown that unlike the blood, the spleen, bone marrow, and peritoneal cavity provide a reservoir for B cells in which they are more resistant to drug depletion [133, 194, 195]. Therefore, depletion efficacy seen in human blood does not necessarily reflect a global depletion. This may be one of the reasons why two randomized, double-blind, phase II/III trials failed to show an effect of Rituximab over placebo in SLE patients [134, 135]. Moreover, drug efficacy may be different between lupus-prone and lupus-resistant mice. Anti-CD20 depletion of B cells has been shown to be much more efficient in BALB/c than in MRL/lpr mice [133]. Therefore, it is crucial to test potential SLE therapies and drugs directly in lupus-prone mice.

There are obvious limitations in evaluating lupus therapies in mouse models. SLE targets the skin, joints, kidneys, and many other organs in humans whereas mouse models of SLE are characterized mainly by the development of nephritis. This is probably due to the fact that the genetic background is far more complicated in lupus patients than in mouse models. Some lupus mice may develop lupus-like symptoms other than renal disease, such as joint swelling and skin rash in a portion of MRL/lpr mice, and pulmonary symptoms in pristane-induced mice (see above). However, no mouse model can mimic the complexity of human lupus. Thus, drugs validated in mouse models may only be effective for a subset of symptoms or patients. To mimic the genetic and pathological heterogeneity in humans, it is crucial to use various mouse models in therapeutic studies. It has been shown that same treatment can have variable effects on different mouse models. For example, treatment with a soluble form of the BAFF receptor (BAFF-R-Ig) induces complete and enduring remission of established nephritis in NZM2410 mice [125], while it is unable to reverse nephritis in NZB/W F1 model unless a soluble form of cytotoxic T-lymphocyte antigen 4 (CTLA4-Ig) is coadministered to block T cell coactivation [131]. This difference is probably due to the fact that nephritic NZB/W F1 mice produce more inflammatory mediators in the kidney than do nephritic NZM2410 mice [125]. Thus, the genetic background should be taken into account when testing therapies on mouse models, and multiple models should be used to ensure

Table 1: Continued.

| Targets                  | Treatment            | Mouse model | Mechanisms                                      | Main outcomes                          | Ref   | Clinical trial |
|--------------------------|----------------------|-------------|-------------------------------------------------|----------------------------------------|-------|----------------|
| Topoisomerase I Inhibitor irinotecan | Topoisomerase I Inhibitor irinotecan | NZB/W F1 | Prevents anti-dsDNA Ab from binding to dsDNA | Survival↑, proteinuria↓, subendothelial immune deposit↓ | [184] |                |
| ACE                      | ACE inhibitor Captopril | NZB/W F1 and MRL/lpr | Reduces TGF-β, IL-4 and IL-10 production | Delayed onset, proteinuria↑, renal lesion↓ | [185] |                |
| HMG-CoA reductase        | HMG-CoA reductase inhibitor Statin | NZB/W F1 | Immunomodulatory effects on B and T cells and APCs | ANA↑, serum urea↑, proteinuria↑, nephritis↑ | [186] |                |
| ACE and HMG-CoA reductase | Coadministration of Statin and ACE inhibitor Imidapril | MRL/lpr | Synergistic effect | Survival↑, ANA↑, proteinuria↑, glomerular deposits↑, renal monocyte attractant CCL2/MCP-1↑ | [187] |                |
| CCL2/MCP-1               | Spiegelmer mNOX-E36 | MRL/lpr | mNOX-E36 blocks CCL2 without induction of IFN-α production | Survival↑, nephritis↑, skin lesion↑, peribronchial inflammation↑ | [188] |                |

* Drug names are shown in italic font.
Confirm association in humans

Spontaneous lupus models

SLE patients

Clinical trials

Therapeutic studies in spontaneous or induced lupus models

Linkage analyses

Association studies

Candidate genes

KO, Tg, or ectopic augmentation

Novel mechanisms of autoimmunity revealed

Candidate gene validation and functional studies

Figure 1: Integration of human and murine studies for new SLE drug discovery. Study of human SLE patients and mouse models of lupus has led to the identification of potential therapeutic targets. In-depth studies in murine models are undertaken to validate the association of the potential targets with disease symptoms. The efficacy of targeted treatments are first tested on murine models of lupus prior to the initiation of human clinical trials.

The applicability of drugs on the more complicated human genetic background.

5. Summary

Murine models are useful tools for the study of the etiology of lupus. A multitude of models exist, each sharing a subset of attributes with SLE observed in humans. In addition, each model affords the study of different aspects of lupus pathogenesis. For example, the cGVHD and pristane-induced models allow for the study of the mechanisms involved at the onset of the disease, while the spontaneous models allow for probing of the genetic causes of disease. NZB/W F1 and DBA → DBF1 can be used to study phenotypes in a gender-biased context similar to that seen in humans. All models are valid candidates for the study of therapeutic interventions.

To date, the use of murine models has identified several novel candidate genes, and some of them have been associated to SLE in humans. Further value in these models is demonstrated by that fact that these genes were not initially identified in human SLE studies. On the other hand, recent genome-wide human studies have identified an array of genes, many of which have no currently described role in lupus. To this effect, murine models allow for forward genetics to identify novel genes that can then be probed using a candidate gene approach to discover their human susceptibility allele counterparts (Figure 1). Conversely, genes identified by human studies can be translated to genetically modified murine models where their roles in lupus pathogenesis can be followed in a forward genetics manner. Both methodologies have proven their usefulness and have the shared goal of identifying novel pathways and targets for disease intervention.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ADCC         | Antibody dependent cell-mediated cytotoxicity |
| aGVHD        | Acute graft-versus-host-disease |
| ALPS         | Autoimmune lymphoproliferative syndrome |
| ANA          | Antinuclear antibody |
| APC          | Antigen presenting cells |
| anti-RNP antibodies | Anti-ribonucleoprotein antibodies: anti-Su, anti-Sm, and anti-U1RNP |
| BAFF-R-Ig    | B-cell-activating factor receptor immunoglobulin |
| CCL          | Chemokine C-C motif ligand |
| CDC          | Complement-dependent cytotoxicity |
| cGVHD        | Chronic graft-versus-host-disease |
| Cr2          | Complement receptor type 2 CR2 (humans) |
| CTLA-4-Ig    | Cytotoxic T-lymphocyte antigen 4 immunoglobulin |
| CTL          | Cytotoxic T cell |
| DC           | Dendritic cell |
| Fcgr2b       | Fc receptor for IgG2b FCGR2B (humans) |
| gld          | Generalized lymphoproliferative disease |
| GN           | Glomerulonephritis |
| gp70         | Glycoprotein 70 |
| GWAS         | Genome wide association studies |
H-2: Murine MHC II
IFNAR: Interferon alpha receptor
IFN I: Type I interferon
IL: Interleukin
ISG: Interferon-stimulated gene
Klk: Kallikrein
KRAB-ZFP: Krüppel-associated box zinc-finger proteins
Marco: Macrophage receptor with collagenous structure
MHC: Major histocompatibility complex
MyD88: Myeloid differentiation primary response gene 88
MZ: Marginal zone
NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells
NZB/W F1: First generation offspring from cross between NZB and NZW
NZB: New Zealand black
NZM: New Zealand mixed
NZW: New Zealand white
Pbx1: Pre-B-cell leukemia transcription factor 1
pDCs: Plasmacytoid dendritic cells
QTL: Quantitative trait loci
SLAM: Signaling lymphocytic activation molecule
SLE: Systemic lupus erythematosus
SNP: Single nucleotide polymorphism
Th1: T helper 1
Th2: T helper 2
th7: Toll-like receptor 7
TMPD: Pristane (2, 6, 10, 14 tetramethylpentadecane)
TNF: Tumor necrosis factor
TNF-R: Tumor necrosis factor receptor
TRAIL: Tumor necrosis factor-related apoptosis-inducing ligand
RBC: Red blood cell
Yaa: Y-linked autoimmune acceleration.

References

[1] K. L. Moser, J. A. Kelly, C. J. Lessard, and J. B. Harley, “Recent insights into the genetic basis of systemic lupus erythematosus,” *Genes and Immunity*, vol. 10, no. 5, pp. 373–379, 2009.

[2] D. H. Kono and A. N. Theofilopoulos, “Genetics of SLE in mice,” *Springer Seminars in Immunopathology*, vol. 28, no. 2, pp. 83–96, 2006.

[3] L. Morel, “Genetics of SLE: evidence from mouse models,” *Nature Reviews Rheumatology*, vol. 6, no. 6, pp. 348–357, 2010.

[4] A. N. Theofilopoulos and F. J. Dixon, “Murine models of systemic lupus erythematosus,” *Advances in Immunology*, vol. 37, pp. 269–390, 1985.

[5] J. R. Roubinian, N. Talal, J. S. Greenspan, J. R. Goodman, and P. K. Sitteri, “Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F mice,” *Journal of Experimental Medicine*, vol. 147, no. 6, pp. 1568–1583, 1978.

[6] U. H. Rudofsky, B. D. Evans, S. L. Balaban, V. D. Mottironi, and A. E. Gabrielson, “Differences in expression of lupus nephritis in New Zealand Mixed H-2(z) homozygous inbred strains of mice derived from New Zealand Black and New Zealand White mice: origins and initial characterization,” *Laboratory Investigation*, vol. 68, no. 4, pp. 419–426, 1993.

[7] L. Morel, U. H. Rudofsky, J. A. Longmate, J. Schiffler, and E. K. Wakeland, “Polygenic control of susceptibility to murine systemic lupus erythematosus,” *Immunity*, vol. 1, no. 3, pp. 219–229, 1994.

[8] S. T. Waters, S. M. Fu, F. Gaskin et al., “NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci,” *Clinical Immunology*, vol. 100, no. 3, pp. 372–383, 2001.

[9] L. Morel, X. H. Tian, B. P. Croker, and E. K. Wakeland, “Epistatic modifiers of autoimmunity in a murine model of lupus nephritis,” *Immunity*, vol. 11, no. 2, pp. 131–139, 1999.

[10] C. Mohan, L. Morel, P. Yang, and E. K. Wakeland, “Genetic dissection of systemic lupus erythematosus pathogenesis: Sle2 on murine chromosome 4 leads to B cell hyperactivity,” *Journal of Immunology*, vol. 159, no. 1, pp. 454–465, 1997.

[11] L. Morel, X. H. Tian, B. P. Croker, and E. K. Wakeland, “Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes,” *Journal of Clinical Investigation*, vol. 101, no. 6, pp. 1362–1372, 1998.

[12] C. Mohan, Y. Yu, L. Morel, P. Yang, and E. K. Wakeland, “Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death,” *Journal of Immunology*, vol. 162, no. 11, pp. 6492–6502, 1999.

[13] L. Morel, C. Mohan, Y. Yu et al., “Functional dissection of systemic lupus erythematosus using congenic mouse strains,” *Journal of Immunology*, vol. 158, no. 12, pp. 6019–6028, 1997.

[14] E. S. Sobel, C. Mohan, L. Morel, J. Schiffler, and E. K. Wakeland, “Genetic dissection of SLE pathogenesis: adoptive transfer of Sle1 mediates the loss of tolerance by bone marrow-derived B cells,” *Journal of Immunology*, vol. 162, no. 4, pp. 2415–2421, 1999.

[15] E. S. Sobel, L. Morel, R. Baert, C. Mohan, J. Schiffler, and E. K. Wakeland, “Genetic dissection of systemic lupus erythematosus pathogenesis: evidence for functional expression of Sle3/5 by non-T cells,” *Journal of Immunology*, vol. 169, no. 7, pp. 4025–4032, 2002.

[16] E. S. Sobel, M. Satoh, Y. Chen, E. K. Wakeland, and L. Morel, “The major murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal functions of both B and T cells,” *Journal of Immunology*, vol. 169, no. 5, pp. 2694–2700, 2002.

[17] S. T. Waters, M. McDuffie, H. Bagavant et al., “Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis,” *Journal of Experimental Medicine*, vol. 199, no. 2, pp. 253–264, 2004.

[18] L. Morel, B. P. Croker, K. R. Blenman et al., “Genetic reconstitution of systemic lupus erythematosus immunopathology with polygenic murine strains,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, no. 12, pp. 6670–6675, 2000.

[19] Z. S. M. Rahman, H. Niu, D. Perry, E. Wakeland, T. Manser, and L. Morel, “Expression of the autoimmune Fcgr2b NZW
allele fails to be upregulated in germinai center B cells and is associated with increased IgG production," *Genes and Immunity*, vol. 8, no. 7, pp. 604–612, 2007.

[20] Y. H. Lee, J. D. Ji, and G. G. Song, "Fcγ receptor IIB and IIIB polymorphisms and susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis," *Lupus*, vol. 18, no. 8, pp. 727–734, 2009.

[21] S. A. Boackle, V. M. Holers, X. Chen et al., "Crz, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein," *Immunity*, vol. 15, no. 5, pp. 775–785, 2001.

[22] Y. Chen, D. Perry, S. A. Boackle et al., "Several genes contribute to the production of autoreactive B and T cells in the murine lupus susceptibility locus Sle1c," *Journal of Immunology*, vol. 175, no. 2, pp. 1080–1089, 2005.

[23] H. Wu, S. A. Boackle, P. Hanivvadhanakul et al., "Association of a common complement receptor 2 haplotype with increased risk of systemic lupus erythematosus," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 10, pp. 3961–3966, 2007.

[24] K. B. Douglas, D. C. Windels, J. Zhao et al., "Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing," *Genes and Immunity*, vol. 10, no. 5, pp. 457–469, 2009.

[25] A. E. Wandstrat, C. Nguyen, N. Limaye et al., "Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine lupus," *Immunity*, vol. 21, no. 6, pp. 769–780, 2004.

[26] K. R. Kumar, L. Li, M. Yan et al., "Regulation of B cell tolerance by the lupus susceptibility gene Ly108," *Science*, vol. 312, no. 5780, pp. 1665–1669, 2006.

[27] D. S. C. Graham, T. J. Vyse, P. R. Fortin et al., "Association of LY9 in UK and Canadian SLE families," *Genes and Immunity*, vol. 9, no. 2, pp. 93–102, 2008.

[28] A. Suzuki, R. Yamada, Y. Kochi et al., "Functional SNPs in CD244 increase the risk of rheumatoid arthritis in a Japanese population," *Nature Genetics*, vol. 40, no. 10, pp. 1224–1229, 2008.

[29] J. Zhu, X. Liu, C. Xie et al., "T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presentation cells," *Journal of Clinical Investigation*, vol. 115, no. 7, pp. 1869–1878, 2005.

[30] K. Liu, Q. Z. Li, A. M. Delgado-Vega et al., "Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans," *Journal of Clinical Investigation*, vol. 119, no. 4, pp. 911–923, 2009.

[31] B. Andrews, R. A. Eisenberg, and A. N. Theofilopoulos, "Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains," *Journal of Experimental Medicine*, vol. 148, no. 5, pp. 1198–1215, 1978.

[32] M. L. Watson, J. K. Rao, G. S. Gilkeson et al., "Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci," *Journal of Experimental Medicine*, vol. 176, no. 6, pp. 1645–1656, 1992.

[33] A. Strasser, P. J. Jost, and S. Nagata, "The many roles of FAS receptor signaling in the immune system," *Immunity*, vol. 30, no. 2, pp. 180–192, 2009.

[34] J. L. Chu, J. Drappa, A. Parnassa, and K. B. Elkon, "The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn," *Journal of Experimental Medicine*, vol. 178, no. 2, pp. 723–730, 1993.

[35] E. A. Reap, D. Leslie, M. Abrahams, R. A. Eisenberg, and P. L. Cohen, "Apoptosis abnormalities of splenic lymphocytes in autoimmune lpr and gld mice," *Journal of Immunology*, vol. 154, no. 2, pp. 936–943, 1995.

[36] T. Takahashi, M. Tanaka, C. I. Brannan et al., "Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand," *Cell*, vol. 76, no. 6, pp. 969–976, 1994.

[37] D. H. Lynch, M. L. Watson, M. R. Alderson et al., "The mouse fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster," *Immunity*, vol. 1, no. 2, pp. 131–136, 1994.

[38] D. T. Teachey, A. E. Seif, and S. A. Grupp, "Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)," *British Journal of Haematology*, vol. 148, no. 2, pp. 205–216, 2010.

[39] D. A. Jabs, R. C. Kuppers, A. M. Saborio et al., "Effects of early and late treatment with anti-CD4 monoclonal antibody on autoimmune disease in MRL/MP-lpr/lpr mice," *Cellular Immunology*, vol. 154, no. 1, pp. 66–76, 1994.

[40] M. J. Shlomchik, M. P. Madiao, D. Ni, M. Trounstein, and D. Huszar, "The role of B cells in lpr/lpr-induced autoimmunity," *Journal of Experimental Medicine*, vol. 180, no. 4, pp. 1295–1306, 1994.

[41] Z. Hao, B. Hampel, H. Yagita, and K. Rajewsky, "T cell-specific ablation of Fas leads to Fas ligand-mediated lymphocyte depletion and inflammatory pulmonary fibrosis," *Journal of Experimental Medicine*, vol. 199, no. 10, pp. 1355–1365, 2004.

[42] S. Izui, V. E. Kelley, and K. Masuda, "Induction of various autoantibodies by mutant gene lpr in several strains of mice," *Journal of Immunology*, vol. 133, no. 1, pp. 227–233, 1984.

[43] P. B. Stranges, J. Watson, C. J. Cooper et al., "Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity," *Immunity*, vol. 26, no. 5, pp. 629–641, 2007.

[44] V. E. Kelley and J. B. Roths, "Interaction of mutant lpr gene with background strain influences renal disease," *Clinical Immunology and Immunopathology*, vol. 37, no. 2, pp. 220–229, 1985.

[45] S. Vidal, D. H. Kono, and A. N. Theofilopoulos, "Loci predisposing to autoimmunity in MRL-Fas(lpr) and C57BL/6-Fas(lpr) mice," *Journal of Clinical Investigation*, vol. 101, no. 3, pp. 696–702, 1998.

[46] M. L. Santiago-Raber, M. K. Haraldsson, A. N. Theofilopoulos, and D. H. Kono, "Characterization of reciprocal Lmb3-4 interval MRL-Fas and C57BL/6-Fas (lpr) mice," *Journal of Clinical Investigation*, vol. 178, no. 12, pp. 8195–8202, 2007.

[47] M. K. Haraldsson, C. A. Louis-Dit-Sully, B. R. Lawson et al., "The lupus-related Lmb3 locus contains a disease-suppressing Coronin-1A gene mutation," *Immunity*, vol. 28, no. 1, pp. 40–51, 2008.

[48] B. Andrews, R. A. Eisenberg, and A. N. Theofilopoulos, "Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains," *Journal of Experimental Medicine*, vol. 148, no. 5, pp. 1198–1215, 1978.

[49] M. A. Maibaum, M. E. K. Haywood, M. J. Walport, and B. J. Morley, "Lupus susceptibility loci map within regions of BXSB derived from the SB/Le parental strain," *Immunogenetics*, vol. 51, no. 4-5, pp. 370–372, 2000.
[50] E. D. Murphy and J. B. Roths, “A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation,” *Arthritis and Rheumatism*, vol. 22, no. 11, pp. 1188–1194, 1979.

[51] R. A. Eisenberg and F. J. Dixon, “Effect of castration on male-determined acceleration of autoimmune disease in BXSB mice,” *Journal of Immunology*, vol. 125, no. 5, pp. 1959–1961, 1980.

[52] C. C. Hudgins, R. T. Steinberg, and D. M. Klinman, “Studies of consomic mice bearing the Y chromosome of the BXSB mouse,” *Journal of Immunology*, vol. 134, no. 6, pp. 3849–3854, 1985.

[53] R. Merino, T. Shibata, S. De Kossodo, and S. Izui, “Differential effect of the autoimmune Ya and lpr genes on the acceleration of lupus-like syndrome in MRL/MpJ mice,” *European Journal of Immunology*, vol. 19, no. 11, pp. 2131–2137, 1989.

[54] P. Pisitkun, J. A. Deane, M. J. DiFilippantonio, T. Tarasenko, A. B. Satterthwaite, and S. Bolland, “Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication,” *Science*, vol. 312, no. 5780, pp. 1669–1672, 2006.

[55] S. Subramanian, K. Tus, Q. Z. Li et al., “A Tlr7 translocation accelerates systemic autoimmunity in murine lupus,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 26, pp. 9970–9975, 2006.

[56] P. von Landenberg and S. Bauer, “Nucleic acid recognizing Toll-like receptors and autoimmunity,” *Current Opinion in Immunology*, vol. 19, no. 6, pp. 606–610, 2007.

[57] E. A. Leadbetter, I. R. Rifkin, A. M. Hohlbaum, B. C. Beaudette, M. J. Shlomchik, and A. Marshak-Rothstein, “Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors,” *Nature*, vol. 416, no. 6881, pp. 603–607, 2002.

[58] C. M. Lau, C. Broughton, A. S. Tabor et al., “RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement,” *Journal of Experimental Medicine*, vol. 202, no. 9, pp. 1171–1177, 2005.

[59] J. A. Deane, P. Pisitkun, R. S. Barrett et al., “Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation,” *Immunity*, vol. 27, no. 5, pp. 801–810, 2007.

[60] A. M. Fairhurst, S. H. Hwang, A. Wang et al., “Yaa autoimmune phenotypes are conferred by overexpression of TLR7,” *European Journal of Immunology*, vol. 38, no. 7, pp. 1971–1978, 2008.

[61] M. L. Santiago-Raber, S. Kikuchi, P. Borel et al., “Evidence for genes in addition to Tlr7 in the Yaa translocation linked with acceleration of systemic lupus erythematosus,” *Journal of Immunology*, vol. 181, no. 2, pp. 1556–1562, 2008.

[62] N. Shen, Q. Fu, Y. Deng et al., “Sex-specific association of X-linked toll-like receptor 7 (TLR7) with male systemic lupus erythematosus,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 36, pp. 15838–15843, 2010.

[63] S. Izui, M. Higaki, D. Morrow, and R. Merino, “The Y chromosome from autoimmune BXSB/MpJ mice induces a lupus-like syndrome in (NZW × C57BL/6)F1 male mice, but not in C57BL/6 male mice,” *European Journal of Immunology*, vol. 18, no. 6, pp. 911–915, 1988.

[64] R. Merino, L. Fossati, M. Lacour, R. Lemoine, M. Higaki, and S. Izui, “H-2-linked control of the Yaa gene-induced acceleration of lupus-like autoimmune disease in BXSB mice,” *European Journal of Immunology*, vol. 22, no. 2, pp. 295–299, 1992.

[65] M. B. Hogarth, J. H. Slingsby, P. J. Allen et al., “Multiple lupus susceptibility loci map to chromosome 1 in BXSB mice,” *Journal of Immunology*, vol. 161, no. 6, pp. 2753–2761, 1998.

[66] M. E. K. Haywood, M. B. Hogarth, J. H. Slingsby et al., “Identification of intervals on chromosomes 1, 3, and 13 linked to the development of lupus in BXSB mice,” *Arthritis and Rheumatism*, vol. 43, no. 2, pp. 349–355, 2000.

[67] M. E. K. Haywood, N. J. Rogers, S. J. Rose et al., “Dissection of BXSB lupus phenotype using mice congenic for chromosome 1 demonstrates that separate intervals direct different aspects of disease,” *Journal of Immunology*, vol. 173, no. 7, pp. 4277–4285, 2004.

[68] L. E. Můžo, K. Lauber, M. Schiller, A. A. Manfredi, and M. Herrmann, “The role of defective clearance of apoptotic cells in systemic autoimmunity,” *Nature Reviews Rheumatology*, vol. 6, no. 5, pp. 280–289, 2010.

[69] I. Hara, S. Izui, and F. J. Dixon, “Murine serum glycoprotein gp70 behaves as an acute phase reactant,” *Journal of Experimental Medicine*, vol. 155, no. 2, pp. 345–357, 1982.

[70] L. Baudino, K. Yoshinobu, N. Morito, M.-L. Santiago-Raber, and S. Izui, “Role of endogenous retroviruses in murine SLE,” *Autoimmunity Reviews*, vol. 10, no. 1, pp. 27–34, 2010.

[71] M. L. Santiago, C. Mary, D. Parzy et al., “Linkage of a major quantitative trait locus to Yaa gene-induced lupus-like nephritis in (NZW × C57BL/6)F1 mice,” *European Journal of Immunology*, vol. 28, no. 12, pp. 4257–4267, 1998.

[72] P. L. Oliver and J. P. Stoye, “Genetic analysis of Gv1, a gene controlling transcription of endogenous murine polytropic proviruses,” *Journal of Virology*, vol. 73, no. 10, pp. 8227–8234, 1999.

[73] L. Baudino, K. Yoshinobu, I. Dunand-Sauthier, L. H. Evans, and S. Izui, “TLR-mediated up-regulation of serum retroviral gp70 is controlled by the Sgp loci of lupus-prone mice,” *Journal of Autoimmunity*, vol. 35, no. 2, pp. 153–159, 2010.

[74] M. Satoh and W. H. Reeves, “Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane,” *Journal of Experimental Medicine*, vol. 180, no. 6, pp. 2341–2346, 1994.

[75] M. Satoh, A. Kumar, Y. S. Kanwar, and W. H. Reeves, “Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 24, pp. 10934–10938, 1995.

[76] M. Satoh, H. B. Richards, V. M. Shaheen et al., “Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane,” *Clinical and Experimental Immunology*, vol. 121, no. 2, pp. 399–405, 2000.

[77] D. L. Smith, X. Dong, S. Du, M. Oh, R. R. Singh, and R. R. Yoskuhl, “A female preponderance for chemically induced lupus in SJL/J mice,” *Clinical Immunology*, vol. 122, no. 1, pp. 101–107, 2007.

[78] H. B. Richards, M. Satoh, M. Shaw, C. Libert, V. Poli, and W. H. Reeves, “Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus,” *Journal of Experimental Medicine*, vol. 188, no. 5, pp. 985–990, 1998.

[79] H. Yoshida, M. Satoh, K. M. Behney et al., “Effect of an exogenous trigger on the pathogenesis of lupus in (NZB × NZW)F1 mice,” *Arthritis and Rheumatism*, vol. 46, no. 8, pp. 2235–2244, 2002.

[80] N. Calvani, M. Satoh, B. P. Croker, W. H. Reeves, and H. B. Richards, “Nephritogenic autoantibodies but absence of nephritis in IL-12p35-deficient mice with pristane-induced
lupus,” *Kidney International*, vol. 64, no. 3, pp. 897–905, 2003.

[81] H. B. Richards, M. Satoh, J. C. Jennette, B. P. Croker, H. Yoshida, and W. H. Reeves, “Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane,” *Kidney International*, vol. 60, no. 6, pp. 2173–2180, 2001.

[82] V. Pascual, L. Farkas, and J. Banchereau, “Systemic lupus erythematosus: all roads lead to type I interferons,” *Current Opinion in Immunology*, vol. 18, no. 6, pp. 676–682, 2006.

[83] D. C. Nacionales, K. M. Kelly-Scumpia, P. Y. Lee et al., “Deficiency of the type I interferon receptor protects mice from experimental lupus,” *Arthritis and Rheumatism*, vol. 56, no. 11, pp. 3770–3783, 2007.

[84] D. L. Thibault, K. L. Graham, L. Y. Lee, I. Balboni, P. J. Hertzog, and P. J. Utz, “Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus,” *Arthritis Research and Therapy*, vol. 11, no. 4, article no. R112, 2009.

[85] L. Rönnblom and V. Pascual, “The innate immune system in SLE: type I interferons and dendritic cells,” *Lupus*, vol. 17, no. 5, pp. 394–399, 2008.

[86] P. Y. Lee, J. S. Weinstein, D. C. Nacionales et al., “A novel type i IFN-producing cell subset in murine lupus,” *Journal of Immunology*, vol. 180, no. 7, pp. 5101–5108, 2008.

[87] P. Y. Lee, YI. Li, Y. Kumagai et al., “Type I interferon modulates monocyte recruitment and maturation in chronic inflammation,” *American Journal of Pathology*, vol. 175, no. 5, pp. 2023–2033, 2009.

[88] P. Y. Lee, Y. Kumagai, YI. Li et al., “TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupus,” *Journal of Experimental Medicine*, vol. 205, no. 13, pp. 2995–3006, 2008.

[89] E. Savarese, C. Steinberg, R. D. Pawar et al., “Requirement of toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis,” *Arthritis and Rheumatism*, vol. 58, no. 4, pp. 1107–1115, 2008.

[90] F. J. Barrat, T. Meeker, J. Gregorio et al., “Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus,” *Journal of Experimental Medicine*, vol. 202, no. 8, pp. 1131–1139, 2005.

[91] V. R. Chowdhary, J. P. Grande, H. S. Luthra, and C. S. David, “Characterization of haemorrhagic pulmonary capillaritis: another manifestation of Pristane-induced lupus,” *Rheumatology*, vol. 46, no. 9, pp. 1403–1410, 2007.

[92] V. A. Nguyen, T. Gotwald, C. Prior, G. Obermoser, and N. Sepp, “Acute pulmonary edema, capillaritis and alveolar hemorrhage: pulmonary manifestations coexistent in antiphospholipid syndrome and systemic lupus erythematosus” *Lupus*, vol. 14, no. 7, pp. 557–560, 2005.

[93] P. H. Wooley, J. R. Seibold, J. D. Whalen, and J. M. Chapdelaine, “Pristane-induced arthritis. The immunologic and genetic features of an experimental murine model of autoimmune disease,” *Arthritis and Rheumatism*, vol. 32, no. 8, pp. 1022–1030, 1989.

[94] M. Potter and J. S. Wax, “Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibility in BALB/cJ with a brief description of pristane-induced arthritis,” *Journal of Immunology*, vol. 127, no. 4, pp. 1591–1595, 1981.
in TNF-α levels,” *Journal of Immunology*, vol. 159, no. 6, pp. 2658–2667, 1997.

[110] S. M. Proudmman, P. G. Conaghan, C. Richardson et al., “Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 43, no. 8, pp. 1790–1800, 2000.

[111] H. Ishida, T. Muchamuel, S. Sakaguchi, S. Andrade, S. Menon, and M. Howard, “Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice,” *Journal of Experimental Medicine*, vol. 179, no. 1, pp. 305–310, 1994.

[112] Z. Yin, G. Bahitrya, NA. Zhang et al., “IL-10 regulates murine lupus,” *Journal of Immunology*, vol. 169, no. 4, pp. 2148–2155, 2002.

[113] K. R. M. Blenman, B. Duan, Z. Xu et al., “IL-10 regulation of lupus in the NZM2410 murine model,” *Laboratory Investigation*, vol. 86, no. 11, pp. 1136–1148, 2006.

[114] C. Gordon, G. E. Ranges, J. S. Greenspan, and D. Wofsy, “Chronic therapy with recombinant tumor necrosis factor α in autoimmune NZB/NZW F mice,” *Clinical Immunology and Immunopathology*, vol. 52, no. 3, pp. 421–434, 1989.

[115] M. Aringer, F. Houssiau, C. Gordon et al., “Adverse events and efficacy of TNF-α blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients,” *Rheumatology (Oxford)*, vol. 48, no. 11, pp. 1451–1454, 2009.

[116] D. Zagury, H. L. Buanecc, A. Mathian et al., “IFNα koinoid vaccine-induced neutralizing antibodies prevent clinical manifestations in a lupus flare murine model,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, no. 13, pp. 5294–5299, 2009.

[117] D. J. Wallace, M. Petri, N. Olsen et al., “MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus,” *Arthritis & Rheumatism*, vol. 56, supplement 9, pp. S526–S527, 2007.

[118] J. M. McBride, D. J. Wallace, Z. Yao et al., “Dose-dependent modulation of interferon regulated genes with administration of single and repeat doses of Rontalizumab in a phase I, placebo controlled, double blind, dose escalation study in SLE,” *Arthritis & Rheumatism*, vol. 60, pp. S775–S776, 2009.

[119] A. Schwarting, K. Paul, S. Tschirner et al., “Interferon-β: a therapeutic for autoimmune lupus in MRL-Fas mice,” *Journal of the American Society of Nephrology*, vol. 16, no. 11, pp. 3264–3272, 2005.

[120] B. R. Lawson, G. J. Prud’homme, Y. Chang et al., “Treatment of murine lupus with cDNA encoding IFN-γR/Fc,” *Journal of Clinical Investigation*, vol. 106, no. 2, pp. 207–215, 2000.

[121] C. O. Jacob, P. H. Van Der Meide, and H. O. McDevitt, “In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to γ interferon,” *Journal of Experimental Medicine*, vol. 166, no. 3, pp. 798–803, 1987.

[122] P. S. Biswas, S. Gupta, E. Chang et al., “Phosphorylation of IRF4 by ROCK2 regulates IL-17 and IL-21 production and the development of autoimmunity in mice,” *Journal of Clinical Investigation*, vol. 120, no. 9, pp. 3280–3295, 2010.

[123] D. Herber, T. P. Brown, S. Liang, D. A. Young, M. Collins, and K. Dunussi-Joannopoulos, “IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression,” *Journal of Immunology*, vol. 178, no. 6, pp. 3822–3830, 2007.

[124] P. Bossi, D. Neumann, E. Del Giudice et al., “IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 2, pp. 14181–14186, 2003.

[125] M. Ramanujam, R. Bethunaickan, W. Huang, H. Tao, M. P. Madaio, and A. Davidson, “Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice,” *Arthritis and Rheumatism*, vol. 62, no. 5, pp. 1457–1468, 2010.

[126] M. F. Petri, J. Merrill, D. J. Wallace et al., “Four-year experience of belimumab, a BlyS-specific inhibitor, in systemic lupus erythematosus (SLE) patients,” *Arthritis & Rheumatism*, vol. 60, 2009.

[127] GlaxoSmithKline press release, “GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of belnysta in systemic lupus erythematosus,” 2009, http://us.gsk.com/html/media-news/pressreleases/2009/2009_pressrelease_10121.htm.

[128] R. M. Smith, M. R. Clatworthy, and D. R. W. Jayne, “Biological therapy for lupus nephritis-tribulations and trials,” *Nature Reviews Rheumatology*, vol. 6, no. 9, pp. 547–552, 2010.

[129] P. Scapini, Y. Hu, C.-L. Chu et al., “Myeloid cells, BAFF, and IFN-γ establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice,” *Journal of Experimental Medicine*, vol. 207, no. 8, pp. 1757–1773, 2010.

[130] J. A. Gross, J. Johnston, S. Mudri et al., “TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease,” *Nature*, vol. 404, no. 6871, pp. 995–999, 2000.

[131] M. Ramanujam, X. Wang, W. Huang et al., “Mechanism of action of transmembrane activator and calcium modulator and ligand interactor-Ig in murine systemic lupus erythematosus,” *Journal of Immunology*, vol. 173, no. 5, pp. 3524–3534, 2004.

[132] W. Liu, A. Szalai, L. Zhao et al., “Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI,” *Arthritis and Rheumatism*, vol. 50, no. 6, pp. 1884–1896, 2004.

[133] A. Ahuja, J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik, “Depletion of B cells in murine lupus: efficacy and resistance,” *Journal of Immunology*, vol. 179, no. 5, pp. 3351–3361, 2007.

[134] J. T. Merrill, C. M. Neuwelt, D. J. Wallace et al., “Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial,” *Arthritis and Rheumatism*, vol. 62, no. 1, pp. 222–233, 2010.

[135] I. Sazn and F. E. H. Lee, “B cells as therapeutic targets in SLE,” *Nature Reviews Rheumatology*, vol. 6, no. 6, pp. 326–337, 2010.

[136] US National Library of Medicine, “A study to evaluate ocrelizumab in patients with nephritis due to systemic lupus erythematosus (BeLONG),” 2010, http://clinicaltrials.gov/ct2/show/NCT00626197.

[137] K. M. Haas, R. Watanabe, T. Matsushita et al., “Protective and pathogenic roles for B cells during systemic autoimmunity in Lyn-deficient mice,” *Journal of Experimental Medicine*, vol. 203, no. 9, pp. 14181–14186, 2003.

[138] T. Dörner, J. Kaufmann, W. A. Wegener, N. Teoh, D. M. Goldenberg, and G. R. Burmester, “Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus,” *Arthritis Research and Therapy*, vol. 8, no. 3, article no. R74, 2006.
[139] UCB press release, “UCB and Immunomedics announce positive results for epratuzumab phase IIb study in systemic lupus erythematosus (SLE),” 2009, http://www.ucb.com/media-room/newsdetail/?id=1337304.

[140] Y. Li, F. Chen, M. Putt et al., “B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice,” Journal of Immunology, vol. 181, no. 5, pp. 2961–2972, 2008.

[141] K. Neubert, S. Meister, K. Moser et al., “The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis,” Nature Medicine, vol. 14, no. 7, pp. 748–755, 2008.

[142] B. K. Finck, P. S. Linsley, and D. Wofsy, “Treatment of murine lupus with CTLA4ig,” Science, vol. 265, no. 5176, pp. 1225–1227, 1994.

[143] D. I. Daikh, B. K. Finck, P. S. Linsley, D. Hollenbaugh, and D. Wofsy, “Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/40L costimulation pathways,” Journal of Immunology, vol. 159, no. 7, pp. 3104–3108, 1997.

[144] US National Library of Medicine, “Abatacept and cyclophosphamide combination therapy for lupus nephritis (ACCeSS),” 2010, http://clinicaltrials.gov/ct2/show/NCT00-1337304.

[145] M. Mihara, I. Tan, Y. Chuzhin et al., “CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus,” Journal of Clinical Investigation, vol. 106, no. 1, pp. 91–101, 2000.

[146] S. A. Oracki, E. Tsantikos, C. Quilici et al., “CTLA4Ig alters the course of autoimmune disease development in Lyn−/− mice,” Journal of Immunology, vol. 184, no. 2, pp. 757–763, 2010.

[147] H. Y. Wu, F. J. Quintana, and H. L. Weiner, “ Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+CD25+CD62L+ regulatory T Cell and is associated with down-regulation of IL-17,” Journal of Immunology, vol. 181, no. 9, pp. 6038–6050, 2008.

[148] Y. L. Hu, D. P. Metz, J. Chung, G. Siu, and M. Zhang, “B7RP-1 blockade ameliorates autoimmunity through regulation of follicular helper T cells,” Journal of Immunology, vol. 182, no. 3, pp. 1421–1428, 2009.

[149] T. L. McGaha, B. Sorrentino, and J. V. Ravetch, “Restoration of tolerance in lupus by targeted inhibitory receptor expression,” Science, vol. 307, no. 5709, pp. 590–593, 2005.

[150] F. J. Barrat, T. Meeker, J. H. Chan, C. Guiducci, and R. L. Coffman, “Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms,” European Journal of Immunology, vol. 37, no. 12, pp. 3582–3586, 2007.

[151] M. Wong, A. La Cava, R. P. Singh, and B. H. Hahn, “Blockade of programmed death-1 in young (New Zealand Black × New Zealand White)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease,” The Journal of Immunology, vol. 185, no. 11, pp. 6563–6571, 2010.

[152] E. R. Bahjat, P. R. Pine, A. Reitsma et al., “An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus,” Arthritis and Rheumatism, vol. 58, no. 5, pp. 1433–1444, 2008.

[153] G. M. Deng, L. Liu, F. R. Bahjat, P. R. Pine, and G. C. Tsokos, “Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice,” Arthritis and Rheumatism, vol. 62, no. 7, pp. 2086–2092, 2010.

[154] D. F. Barber, A. Bartolomé, C. Hernandez et al., “PI3K inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus,” Nature Medicine, vol. 11, no. 9, pp. 933–935, 2005.

[155] S. L. Lui, R. Tsang, K. W. Chan et al., “Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice,” Nephrology Dialysis Transplantation, vol. 23, no. 9, pp. 2768–2776, 2008.

[156] D. Fernandez, E. Bonilla, N. Mirza, B. Niland, and A. Perl, “Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2983–2988, 2006.

[157] P. A. Blair, K. A. Chavez-Rueda, J. G. Evans et al., “Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice,” Journal of Immunology, vol. 182, no. 6, pp. 3492–3502, 2009.

[158] K. J. Scalapino, Q. Tang, J. A. Bluestone, M. L. Bonyhadi, and D. I. Daikh, “Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells,” Journal of Immunology, vol. 177, no. 3, pp. 1451–1459, 2006.

[159] K. J. Scalapino and D. I. Daikh, “Suppression of glomerulonephritis in NZB/NZW lupus prone mice by adoptive transfer of Ex vivo expanded regulatory T cells,” PLoS One, vol. 4, no. 6, Article ID e6031, 2009.

[160] Z. Gu, K. Akiyama, X. Ma et al., “Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice,” Lupus, vol. 19, no. 13, pp. 1502–1514, 2010.

[161] J. Liang, H. Zhang, B. Hua et al., “Allogeneic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study,” Annals of the Rheumatic Diseases, vol. 69, no. 8, pp. 1423–1429, 2010.

[162] J. Chang, S. Hung, H. Wu et al., “Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis,” Cell Transplantation. In press.

[163] F. Schena, C. Gambini, A. Gregorio et al., “Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2776–2786, 2010.

[164] M. Duvic, A. D. Steinberg, and L. W. Klassen, “Effect of the anti-estrogen, nafoxidine, on NZB/W autoimmune disease,” Arthritis and Rheumatism, vol. 21, no. 4, pp. 414–417, 1978.

[165] A. D. Sturgess, D. T. P. Evans, I. R. Mackay, and A. Riglar, “Effects of the oestrogen antagonist tamoxifen on disease indices in systemic lupus erythematosus,” Journal of Clinical and Laboratory Immunology, vol. 13, no. 1, pp. 11–14, 1984.

[166] Z. M. Schloeger, H. Zinger, and E. Mozes, “Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of NZB×NZW/F1 female mice are associated with specific reduction of IgG3 autoantibodies,” Annals of the Rheumatic Diseases, vol. 62, no. 4, pp. 341–346, 2003.

[167] W. M. Wu, B. E. Lin, Y. C. Su, J. L. Suen, and B. L. Chiang, “Tamoxifen decreases renal inflammation and alleviates disease severity autoimmune NZB/W F1 mice,” Scandinavian Journal of Immunology, vol. 52, no. 4, pp. 393–400, 2000.

[168] N. I. Abdou, V. Rider, C. Greenwell, X. Li, and B. F. Kimber, “Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell
activation marker studies: a double-blind placebo-controlled trial,” Journal of Rheumatology, vol. 35, no. 5, pp. 797–803, 2008.

[169] Y. Zhang, S. Saha, G. Rosenfeld, J. Gonzalez, K. P. Pepeljugoski, and E. Peeva, “Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice,” Journal of Rheumatology, vol. 37, no. 8, pp. 1646–1657, 2010.

[170] X. J. Yan, M. Qi, G. Télusma et al., “Indole-3-carbinol improves survival in lupus-prone mice by inducing tandem B- and T-cell differentiation blockades,” Clinical Immunology, vol. 131, no. 3, pp. 481–494, 2009.

[171] J. R. Roubinian, R. Papoian, and N. Talal, “Androgenic hormones modulate autoantibody responses and improve survival in murine lupus,” Journal of Clinical Investigation, vol. 59, no. 6, pp. 1066–1070, 1977.

[172] L. Moszkorozvá, Z. Lacinová, J. Marek, L. Musilová, A. Dohnalová, and C. Dostál, “Hyperprolactinemia in patients with systemic lupus erythematosus,” Clinical and Experimental Rheumatology, vol. 20, no. 6, pp. 807–812, 2002.

[173] A. D. Steinberg, J. B. Roths, and E. D. Murphy, “Effects of thymectomy or androgen administration upon the autoimmune disease of MRL-Mp-lpr mice,” Journal of Immunology, vol. 125, no. 2, pp. 871–873, 1980.

[174] H. Amital, M. Heilweil, R. Ulmansky et al., “Treatment with a laminin-derived peptide suppresses lupus nephritis,” Journal of Immunology, vol. 175, no. 8, pp. 5516–5523, 2005.

[175] F. Monneaux, J. M. Lozano, M. E. Patarroyo, J. P. Briand, and S. Muller, “T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K saKNP protein administered in MRL/lpr mice,” European Journal of Immunology, vol. 33, no. 2, pp. 287–296, 2003.

[176] N. Page, N. Schall, J.-M. Strub et al., “The spicosemicos phosphopeptide P140 controls the lupus disease by interacting with the HSC70 protein and via a mechanism mediated by γδ T cells,” PLoS One, vol. 4, no. 4, article e5273, 2009.

[177] S. Muller, F. Monneaux, N. Schal et al., “Spicosemicos peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial,” Arthritis and Rheumatism, vol. 58, no. 12, pp. 3873–3883, 2008.

[178] A. Kalyaperumal, M. A. Michaels, and S. K. Datta, “Antigen-presenting therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of the chronic graft-versus-host model of systemic lupus erythematosus,” Journal of Immunology, vol. 162, no. 10, pp. 5775–5783, 1999.

[179] Y. Ozaki, R. Amakawa, T. Ito et al., “Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus,” Arthritis and Rheumatism, vol. 44, no. 2, pp. 432–441, 2001.

[180] B. H. Hahn, R. P. Singh, A. La Cava, and F. M. Ebling, “Tolerogetic treatment of lupus mice with consensus peptide induces Foxp3–expressing, apoptosis-resistant, TGFβ-secretory CD8+ T cell suppressors,” Journal of Immunology, vol. 175, no. 11, pp. 7728–7737, 2005.

[181] R. P. Singh, A. La Cava, and B. H. Hahn, “A consensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB × NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules,” Journal of Immunology, vol. 180, no. 4, pp. 2069–2080, 2008.

[182] E. Mozes and A. Sharabi, “A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus,” Autoimmunity Reviews, vol. 10, no. 1, pp. 22–26, 2010.

[183] N. Mishra, C. M. Reilly, D. R. Brown, P. Ruiz, and G. S. Gilkeson, “Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse,” Journal of Clinical Investigation, vol. 111, no. 4, pp. 539–552, 2003.

[184] M. Frese-Scheraper, J. Zbaeren, M. Gugger, M. Monestier, and S. Frese, “Reversal of established lupus nephritis and prolonged survival of New Zealand Black × New Zealand White mice treated with the topoisomerase I inhibitor irinotecan,” Journal of Immunology, vol. 184, no. 4, pp. 2175–2182, 2010.

[185] D. A. De Albuquerque, V. Saxena, D. E. Adams et al., “An ACE inhibitor reduces Th2 cytokines and TGF-β1 and TGF-β2 isoforms in murine lupus nephritis,” Kidney International, vol. 65, no. 3, pp. 846–859, 2004.

[186] S. Lawman, C. Mauri, E. C. Jury, H. T. Cook, and M. Ehrenstein, “Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice,” Journal of Immunology, vol. 173, no. 12, pp. 7641–7646, 2004.

[187] H. Shimazu, K. Kinoshita, S. Hino et al., “Effect of combining ACE inhibitor and statin in lupus-prone mice,” Clinical Immunology, vol. 136, no. 2, pp. 188–196, 2010.

[188] O. Kulkarni, R. D. Pawar, W. Purschke et al., “Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice,” Journal of the American Society of Nephrology, vol. 18, no. 8, pp. 2350–2358, 2007.

[189] F. Chen, M. A. Maldonado, M. Madaio, and R. A. Eisenberg, “The role of host (endogenous) T cells in chronic graft-versus-host autoimmunity disease,” Journal of Immunology, vol. 161, no. 11, pp. 5880–5885, 1998.

[190] A. Choudhury, M. A. Maldonado, P. L. Cohen, and R. A. Eisenberg, “The role of host CD4 T cells in the pathogenesis of the chronic graft-versus-host model of systemic lupus erythematosus,” Journal of Immunology, vol. 174, no. 12, pp. 7600–7609, 2005.

[191] A. Choudhury, P. L. Cohen, and R. A. Eisenberg, “B cells require “nurturing” by CD4 T cells during development in order to respond in chronic graft-versus-host model of systemic lupus erythematosus,” Clinical Immunology, vol. 136, no. 1, pp. 105–115, 2010.

[192] A. C. Chan and P. J. Carter, “Therapeutic antibodies for autoimmunity and inflammation,” Nature Reviews Immunology, vol. 10, no. 5, pp. 301–316, 2010.

[193] N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder, “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 42, pp. 15178–15183, 2005.

[194] Y. Hamaguchi, J. Uchida, D. W. Cain et al., “The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice,” Journal of Immunology, vol. 184, no. 4, pp. 2175–2182, 2010.